Silo Pharma, Inc. (NASDAQ: SILO)

Silo Pharma, Inc. (SILO), a developmental stage biopharmaceutical company, operates in the healthcare industry with a focus on creating novel therapeutics for conditions such as PTSD, stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. The company distinguishes itself by developing unique therapies that combine both conventional drugs and psychedelic formulations.

Silo Pharma generates revenue through the development and commercialization of its product candidates, which include SPC-15, SP-26, SPC-14, and SPU-16. SPC-15 is a prophylactic therapeutic composition designed to treat and prevent stress-induced affective disorders, including PTSD. SP-26 is a time-release ketamine-based loaded implant that alleviates fibromyalgia and chronic pain. SPC-14 is a novel drug that combines two approved therapeutics for the treatment of Alzheimer's disease. SPU-16 is a novel peptide that targets inflamed CNS areas, with an initial indication for multiple sclerosis.

The company's position within the industry is strengthened by its focus on developing novel therapies for underserved conditions. Silo Pharma's competitive advantages include its expertise in developing innovative therapies, its collaborations with leading universities and research institutions, and its dedication to advancing the field of psychedelic medicine. The company's competitors include established players and emerging companies in the biopharmaceutical industry, but Silo Pharma's unique focus on novel therapeutics and its partnerships with leading universities and research institutions position it well for success in the market.

Silo Pharma's customers include leading universities and research institutions, as well as potential pharmaceutical partners. The company's product candidates have the potential to treat a range of conditions, including PTSD, fibromyalgia, and multiple sclerosis.

In terms of its product development pipeline, Silo Pharma has multiple product candidates in various stages of development. The company has entered into several license agreements and sponsored research agreements with leading universities and research institutions, including Columbia University, University of Maryland, Baltimore, and The Regents of the University of California.

Silo Pharma's commitment to protecting its intellectual property includes obtaining, maintaining, and enforcing patent protection for its products, formulations, processes, methods, and other proprietary technologies. The company has established business procedures to maintain the confidentiality of its proprietary information and has obtained intellectual property rights, including issued patents and pending patent applications.

The company is subject to extensive regulation by the FDA and other regulatory authorities, including requirements for preclinical and clinical studies, manufacturing, quality control, and marketing. Failure to comply with these regulations could result in enforcement action, including civil penalties, product seizures, and criminal prosecution.

As of March 23, 2024, Silo Pharma employed three full-time employees and believes that it maintains good relations with its employees. The company was incorporated as Gold Swap, Inc. in 2010 and changed its name to Silo Pharma, Inc. in 2020. Silo Pharma is a developmental stage company primarily engaged in merging traditional therapeutics with psychedelic research.